US 12,465,029 B2
Genetically modified cells, tissues, and organs for treating disease
Bernhard J. Hering, Minnetonka, MN (US); and Christopher Burlak, Minnetrista, MN (US)
Assigned to Regents of the University of Minnesota, Minneapolis, MN (US)
Filed by REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Filed on Sep. 21, 2021, as Appl. No. 17/480,404.
Application 17/480,404 is a continuation of application No. 16/944,042, filed on Jul. 30, 2020, granted, now 11,234,418.
Application 16/944,042 is a continuation of application No. 16/295,887, filed on Mar. 7, 2019, granted, now 10,993,419, issued on May 4, 2021.
Application 16/295,887 is a continuation of application No. 15/793,901, filed on Oct. 25, 2017, granted, now 10,278,372, issued on May 7, 2019.
Application 15/793,901 is a continuation of application No. 14/965,451, filed on Dec. 10, 2015, granted, now 9,888,673, issued on Feb. 13, 2018.
Claims priority of provisional application 62/253,493, filed on Nov. 10, 2015.
Claims priority of provisional application 62/090,037, filed on Dec. 10, 2014.
Prior Publication US 2022/0104467 A1, Apr. 7, 2022
Int. Cl. A01K 67/027 (2024.01); A01K 67/0275 (2024.01); A61K 31/436 (2006.01); A61K 31/675 (2006.01); A61K 35/12 (2015.01); A61K 35/15 (2025.01); A61K 35/26 (2015.01); A61K 35/28 (2015.01); A61K 35/39 (2015.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C12N 5/071 (2010.01); C12N 15/113 (2010.01)
CPC A01K 67/0275 (2013.01) [A61K 31/436 (2013.01); A61K 31/675 (2013.01); A61K 35/12 (2013.01); A61K 35/15 (2013.01); A61K 35/26 (2013.01); A61K 35/28 (2013.01); A61K 35/39 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); C07K 16/2833 (2013.01); C07K 16/2866 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C12N 5/0676 (2013.01); C12N 5/0677 (2013.01); A01K 2217/15 (2013.01); A01K 2227/108 (2013.01); A01K 2267/025 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C12N 15/113 (2013.01); C12N 2310/10 (2013.01); C12N 2310/20 (2017.05)] 20 Claims
 
1. A tolerizing regimen for administration to a human subject, the tolerizing regimen comprising:
a tolerizing cell vaccine that comprises apoptotic leukocytes that comprise leukocytes chemically cross-linked with a crosslinking agent, wherein the leukocytes are human leukocytes or leukocytes from a member of a Laurasiatheria superorder;
an mTOR inhibitor;
a tumor necrosis factor alpha inhibitor;
an interleukin 6 inhibitor; and
an anti-CD40 agent or an anti-CD-154 agent;
wherein said tolerizing regimen is formulated as one or more compositions that upon administration to a human subject result in a reduced T-cell activation in the human subject as compared to the T-cell activation in said subject absent said administration.